logo
Twitter
Discord
Email
logo
Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited

NASDAQ•RGC
CEO: Mr. Yat-Gai Au
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2021-07-16
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Contact Information
Chinachem Leighton Plaza, 9th Floor 29 Leighton Road, Causeway Bay, Hong Kong
852-2155-0823
www.regencellbioscience.com
Market Cap
$13.56B
P/E (TTM)
-3784.3
33.1
Dividend Yield
--
52W High
$83.60
52W Low
$0.09
52W Range
33%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.00+0.00%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net losses decreased 18% to $3.58M in FY2025 from $4.36M in FY2024, reflecting improved operational efficiency.
Operating Expenses Down 20% Total operating expenses fell 20% to $3.77M in FY2025 compared to $4.74M last year, driven by lower marketing spend.
Cash Burn Rate Decreased Net cash used in operating activities improved 22%, totaling $3.11M used in FY2025 versus $4.00M used in FY2024.
CEO Maintains Strong Control Founder Yat-Gai Au beneficially owns 88.6% of Ordinary Shares, ensuring significant influence over corporate decisions and strategy.

Risk Factors

Continued Operating Losses Expected Company expects to incur increasing operating losses for the foreseeable future as product development costs continue without revenue generation.
Substantial Going Concern Doubt Management concluded substantial doubt exists regarding ability to continue as a going concern without securing necessary additional capital financing.
Regulatory Approval Dependency Business success is entirely dependent on timely completion of research studies and obtaining regulatory approval for the TCM formula.
Unproven TCM Formula Efficacy Efficacy results stem from uncontrolled studies; standardized formula has not yet demonstrated safety or efficacy comparable to established treatments.

Outlook

Focus on Hong Kong Launch Primary goal is to commercialize the standardized liquid-based TCM formula initially within the Hong Kong market after regulatory success.
Seek Pharmaceutical Partnerships Aim to form partnerships with leading pharmaceutical companies to accelerate R&D efforts for upcoming clinical trials and data integrity.
Explore Broader TCM Applications Intend to conduct further research on the TCM base formula for potential wider application across other neurological disorders.
Integrate Digital Health Ecosystem Concept planning underway to integrate AI algorithms, Blockchain technology, and cryptocurrency to optimize stakeholder value creation.

Peer Comparison

Revenue (TTM)

DaVita Inc.DVA
$13.32B
+5.1%
Grifols, S.A.GRFS
$8.30B
+7.3%
Avantor, Inc.AVTR
$6.58B
-3.6%

Gross Margin (Latest Quarter)

Verona Pharma plcVRNA
95.4%
+0.0pp
Elanco Animal Health IncorporatedELAN
53.4%
+14.1pp
Repligen CorporationRGEN
53.2%
+3.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VRNA$72.68B-145.1-30.0%42.7%
RVMD$23.25B-23.7-49.2%7.0%
RGC$13.56B-3784.3-61.9%9.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 20-F - FY 2025

    Period End: Jun 30, 2025|Filed: Oct 31, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.01+17.2%
    N/A

  • Form 20-F - FY 2024

    Period End: Jun 30, 2024|Filed: Oct 25, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.01+26.9%
    N/A

  • Form 20-F - FY 2023

    Period End: Jun 30, 2023|Filed: Oct 27, 2023|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.01+20.7%
    N/A

  • Form 20-F - FY 2022

    Period End: Jun 30, 2022|Filed: Oct 31, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.01-435.7%
    N/A

  • Form 20-F - FY 2021

    Period End: Jun 30, 2021|Filed: Oct 29, 2021|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.00-64.7%
    N/A